Clinical Trial: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06879470) titled 'JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma' on March 11.

Brief Summary: This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma.

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: B-Non Hodgkin Lymphoma

Intervention: DRUG: JY231 Injection

This is an open-label, single-arm study to evaluate the effi...